Abolishing spontaneous epileptiform activity in human brain tissue through AMPA receptor inhibition

Sukhvir K. Wright, Max A. Wilson, Richard Walsh, William B. Lo, Nilesh Mundil, Shakti Agrawal, Sunny Philip, Stefano Seri, Stuart D. Greenhill & Gavin L. Woodhall

1Aston Neuroscience Institute, School of Life and Health Sciences, Aston University, Birmingham, UK
2Department of Paediatric Neurology, The Birmingham Women’s and Children’s Hospital, NHS Foundation Trust, Birmingham, UK
3Department of Paediatric Neurosurgery, The Birmingham Women’s and Children’s Hospital, NHS Foundation Trust, Birmingham, UK
4Department of Clinical Neurophysiology, The Birmingham Women’s and Children’s Hospital, NHS Foundation Trust, Birmingham, UK

Correspondence
Gavin L. Woodhall, School of Life and Health Sciences, Aston University, Birmingham B4 7ET, UK. Tel: +44 (0)121 204 3995; Fax: +44 (0)121 204 3696; E-mail: g.l.woodhall@aston.ac.uk

Abstract
Objective: The amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) is increasingly recognized as a therapeutic target in drug-refractory pediatric epilepsy. Perampanel (PER) is a non-competitive AMPAR antagonist, and pre-clinical studies have shown the AMPAR-mediated anticonvulsant effects of decanoic acid (DEC), a major medium-chain fatty acid provided in the medium-chain triglyceride ketogenic diet. Methods: Using brain tissue resected from children with intractable epilepsy, we recorded the effects of PER and DEC in vitro. Results: We found resected pediatric epilepsy tissue exhibits spontaneous epileptiform activity in vitro, and showed that DEC and PER inhibit this epileptiform activity in local field potential recordings as well as excitatory synaptic transmission. Interpretation: This study confirms AMPAR antagonists inhibit epileptiform discharges in brain tissue resected in a wide range of pediatric epilepsies.

Introduction
Molecular targets for pediatric epilepsy treatment have largely centered on voltage-gated sodium and calcium channels. The recent introduction of Perampanel (PER), a non-competitive amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) antagonist, has introduced the concept of AMPAR modulation as an effective anticonvulsant strategy. Similarly, recent studies in epilepsy rodent models have demonstrated the anti-epileptic action of decanoic acid (DEC), a major medium-chain fatty acid provided in the medium-chain triglyceride (MCT) ketogenic diet (KD), is mediated through direct and selective inhibition of AMPARs.

Human tissue samples provide a valuable tool for preclinical drug screening and mechanism-of-action epilepsy studies. This is particularly useful in pediatrics, where few anticonvulsant drug trials include children and adult study results are often extrapolated to children with pediatricians prescribing “off-label”. In most human brain tissue preparations, epileptiform activity is induced through manipulation of artificial cerebrospinal fluid (aCSF) magnesium or potassium or by adding pro-convulsant agents (e.g. 4-aminopyridine). We have found pediatric human brain tissue to be hyperexcitable and have recorded spontaneous epileptic activity. We show that antagonism of AMPAR has a profound anticonvulsant effect in tissue derived from a spectrum of difficult-to-treat seizure syndromes.
Methods

**Human tissue collection and slice preparation**

Human tissue was obtained with informed consent from pediatric patients undergoing epilepsy surgery at Birmingham Children’s Hospital. Ethical approval was obtained from the Black Country Local Ethics Committee (10/H1202/23; 30 April 2010), and from Aston University’s ethics committee (Project 308 cellular studies in epilepsy) and through the Research and Development Department at Birmingham Children’s Hospital (IRAS ID12287). Specimens were resected intraoperatively with minimal traumatic tissue damage, and minimal use of electrocautery. For transport to the laboratory, samples were transferred immediately to ice-cold choline-based artificial cerebrospinal fluid (aCSF) standardized for use in human tissue experiments8–11 containing in mmol/L: 110 choline chloride, 26 NaHCO3, 10 D-glucose, 11.6 ascorbic acid, 7 MgCl2, 3.1 sodium pyruvate, 2.5 KCl, 1.25 NaH2PO4 and 0.5 CaCl2 with added 0.04 indomethacin and 0.3 uric acid for neuroprotection, and bubbled with carbogen (95% O2, 5% CO2). For slice storage and experiments, aCSF containing (in mmol/L): 125 NaCl, 3 KCl, 1.6 MgSO4, 1.25 NaH2PO4, 26 NaHCO3, 2 CaCl2, 10 Glucose, was used.

**Local field potential (LFP) recordings**

About 450 µm thick brain slices were prepared and stored and recordings made as previously reported.12 Epileptiform events were classified as activity displaying an amplitude fourfold greater than the root mean square baseline amplitude, providing the event count, while the time difference between these events provided the interevent interval (IEI). Statistical analysis was conducted using Prism 8. Measurements expressed as median (M), interquartile range (Q1–Q3) and min–max values.

**Whole-cell patch-clamp (WCPC) recordings**

Whole-cell recordings were made using standard techniques.13 Electrodes were filled with an internal solution containing (in mmol/L): 100 CsCl, 40 HEPES, 1 Qx-314, 0.6 EGTA, 5 MgCl2, 10 TEA-Cl, 4 ATP-Na, 0.3 GTP-Na (titrated with CsOH to pH 7.25) at 290–295 mOsm for IPSCs. Also included in the electrode was the electrode was 1–3 mmol/L 1 IEM 1460, which blocks ionotropic glutamate receptors from inside the cell.13 For EPSCs the internal solution contained (in mmol/L): 100 Cs-glutamate, 40 HEPES, 1 Qx-314, 0.6 EGTA, 2 NaCl, 5 Mg-glutamate, 5 TEA-Cl, 10 Phospho-Creatinine, 4 ATP-Na, 0.3 GTP-Na (titrated with CsOH to pH 7.3) at 285 mOsm. The EPSCs and IPSCs were recorded as apparent inward currents at −70 mV using Axopatch 200B amplifier (Molecular Devices, San Jose, CA, USA). Signals were low-pass filtered at 5 kHz with an 8-pole Bessel filter and digitized at 10 kHz using a Digidata 1440A and pClamp software (Molecular Devices). Data were analyzed using Axograph and Prism 8. Measurements are expressed as mean median ± SEM.

**Drugs**

DEC (Sigma, Dorset, UK) and PER (Eisai, Hatfield, UK) were prepared as 1 M stock using dimethyl sulfoxide.

**Results**

**Patient data**

Brain tissue was obtained from 16 patients (F:M 9:7), median age 10.5 years (range 3–18 years). Surgical procedures included temporal resection (seven), hemispherectomy (five), occipital lobectomy (one), and frontal resection (three). One patient was on the modified KD pre-surgery (Table 1).

**DEC reduces spontaneous epileptiform activity in paediatric epilepsy tissue in vitro**

LFP recordings were assessed for spontaneous epileptiform activity (Fig. 1B) before addition of DEC at increasing concentrations (Fig. 1A). DEC significantly reduced the frequency of epileptiform events per minute compared to control conditions (control [M = 2.46, Q1–Q3 = 1.47–2.84, min–max = 0.53–3.10; n = 5] vs. 300 µmol/L [M = 0.25, Q1–Q3 = 0.14–0.78, min–max = 0.13–0.88; n = 5, P < 0.05] and 1 mmol/L concentrations [M = 0.25, Q1–Q3 = 0.08–0.45, min–max = 0.02–0.62; n = 5, P < 0.05]; Friedman test with Dunn’s post-test; Fig. 1C). The IEI of epileptic activity increased significantly with all concentrations of DEC (Control [M = 3.18 sec, Q1–Q3 = 0.75–7.33 sec; n = 5] vs. 100 µmol/L [M = 6.76 sec, Q1–Q3 = 2.87–16.40 sec; n = 5, P < 0.005], 300 µmol/L [M = 12.12 sec, Q1–Q3 = 5.44–26.01 sec; n = 5, P < 0.005] and 1 mmol/L [M = 26.11 sec, Q1–Q3 = 8.29–51.27 sec; n = 5, P < 0.005]; Kruskal–Wallis with Dunn’s post-test; Fig. 1D).

**DEC inhibits excitatory but not inhibitory postsynaptic currents**

The effects of DEC on synaptic activity were investigated using the WCPC technique to assess spontaneous
The effect of DEC in the presence of tetrodotoxin (TTX, 1 μmol/L). As Figure 1H shows, after addition of TTX there was a significant reduction of amplitude (20.9 ± 1.9 vs. 18.2 ± 0.8 pA, n = 6 cells, P = 0.03), but no significant change in the IEI of mEPSCs (Fig. 1I; 627 ± 172 vs. 656.5 ± 211 msec, n = 6 cells, P = ns) or charge transfer (Fig. 1J; 192 ± 127 vs. 195 ± 60 fC, n = 6, P = 0.5) with 1 mmol/L DEC, suggesting DEC may act on postsynaptic AMPARs.

Since inhibitory interneurons are subject to glutamatergic drive, any change in AMPAR activity is likely to depress gamma-aminobutyric acid (GABA) release and, indeed, we have seen this in recordings where PER is applied. It seems unlikely, however, that DEC would have any direct effect on GABA release. To investigate the actions of DEC on isolated inhibitory synaptic currents, we used whole-cell patch electrodes filled with the ionotropic glutamate receptor channel blocker, IEM-1460, at 1.5 mmol/L. Under these conditions, in which AMPARs were blocked from inside the recorded cell, we recorded miniature IPSCs (mIPSCs) from principal neurons in the presence of TTX 1 μmol/L (Fig. 1K). Analysis of pooled data revealed no significant change in amplitude, (28.9 ± 2.5 vs. 30.1 ± 2.2 pA, n = 5, P = ns), IEI of recorded mIPSCs after addition of 1 mmol/L DEC (Fig. 1L; 129.3 ± 10.9 vs. 96.6 ± 14.3 msec, n = 5, P = ns), or charge transfer (Fig. 1M; 4912 ± 728 vs. 5751 ± 2503 fQ, n = 5, P = ns).

**PER abolishes spontaneous epileptiform activity in pediatric epilepsy tissue in vitro**

LFP recordings were assessed for spontaneous epileptiform activity (Fig. 2B) before addition of PER (Fig. 2A). PER significantly reduced the number of epileptiform events per minute compared to control conditions (control [M = 1.48, Q1–Q3 = 0.63–2.20, min–max = 0.47–4.33; n = 7] vs. PER 10 μmol/L [M = 0.35, Q1–Q3 = 0.13–0.83, min–max = 0.05–0.87]; n = 7, P < 0.05; Wilcoxon test Fig. 2C). Application of PER also increased the IEI (Fig. 2D; control [M = 2.89 sec, Q1–Q3 = 0.89–7.51 sec; n = 7] vs. 10 μmol/L PER [M = 12.01 sec, Q1–Q3 = 3.50–27.48 sec; n = 7], P < 0.005).

**PER inhibits excitatory but not inhibitory postsynaptic currents**

To gain a better understanding of PER’s ability to abolish spontaneous epileptiform activity, recordings of neurotransmitter release were conducted (Fig. 2E–J). Recordings revealed that principal neurons received GABAergic IPSCs with a mean median IEI of 96.99 ± 23.23 msec (Fig. 2F) and a mean median amplitude of

---

**Table 1. Patient data.**

| Patient | Operation | Medication | Histology |
|---------|-----------|------------|-----------|
| 1       | Right frontal disconnection and resection | Modified KD, Sodium valproate, Vigabatrin | No definite abnormal pathology |
| 2       | Left temporal lobectomy | Topiramate, Carbamazepine | Gliosis |
| 3       | Right temporal lobectomy | Lamotrigine | Gliosis, in keeping with secondary changes associated with epilepsy |
| 4       | Hemispherotomy | Clonazepam, Carbamazepine, Levetiracetam | Gliosis |
| 5       | Left temporal lobectomy and Clobazam Levetiracetam Lamotrigine | | hippocampectomy |
| 6       | Left temporal lobectomy | Lamotrigine | Hippocampal sclerosis |
| 7       | Hemispherotomy | Oxcarbazepine, Levetiracetam | Gliosis, in keeping with secondary changes associated with epilepsy |
| 8       | Left temporal lobectomy | Topiramate, Carbamazepine | Low grade glioma, neoplasm |
| 9       | Left temporal lobectomy | Carbamazepine | Hippocampal sclerosis |
| 10      | Occipital lobectomy | Lamotrigine, Sodium valproate | Cortical damage |
| 11      | Frontal resection | Topiramate, Clobazam, Levetiracetam | Focal cortical dysplasia Type IIB |
| 12      | Frontal resection | Carbamazepine, Brivacetam | Focal cortical dysplasia Type IA |
| 13      | Temporal lobectomy | Levetiracetam, Carbamazepine | Mesial temporal sclerosis |
| 14      | Hemispherotomy Topiramate, Carbamazepine, Clobazam | | Focal cortical dysplasia |
| 15      | Hemispherotomy | Lamotrigine, Carbamazapine, Levetiracetam | Rasmussen’s and microencephalitis |
| 16      | Hemispherotomy | Carbamazepine | Polymicrogyria |

---

excitatory and inhibitory postsynaptic currents (sEPSCs/sIPSCs; Fig. 1E–M). As Figure 1F shows, application of 1 mmol/L DEC significantly increased the IEI (248 ± 145 vs. 752 ± 175 msec, n = 6 cells, P = 0.03) with no change in the amplitude of sEPSCs (19.8 ± 1.9 vs. 17.4 ± 1.2 pA, n = 6, P = 0.1), or charge transfer (Fig. 1G; 641 ± 265 vs. 350 ± 114 fC, n = 6, P = 0.5). We next tested the location of the DEC effects by testing...
Ampa Receptor Inhibition in Spontaneously Epileptic Human Brain Tissue

S. K. Wright et al.
Ampa Receptor Inhibition in Spontaneously Epileptic Human Brain Tissue

S. K. Wright et al.

Figure 1. Decanoic acid reduces spontaneous epileptiform activity in pediatric epilepsy tissue samples. (A) Example trace of local field potential recording before and after consecutive addition of DEC. Scale bar 100 µV versus 60 sec. (B) Two examples of spontaneous epileptiform activity from separate pediatric human tissue recordings. Black bar denotes zoomed in section of events. Scale bars (top) 40 µV versus 500 msec, (bottom) 100 µV versus 2 sec. (C) Pooled events per minute under various conditions. (D) The interevent interval in different concentrations of DEC. (E) Example trace of sEPSCs from pediatric human tissue before (top) and after (bottom) treatment with 1 mmol/L DEC. Scale bar 50 pA versus 1 sec. (F) Pooled mean-median inter-event interval in 1 mmol/L DEC. (G) Pooled mEPSC charge transfer in 1 mmol/L DEC. (H) Pooled mean-medium amplitude of sEPSCs in 1 mmol/L DEC. (I) Pooled inter-event interval of mEPSCs with 1 mmol/L DEC. (J) Pooled charge transfer of mEPSCs in 1 mmol/L DEC. (K) Example traces of mIPSC recordings pre and post addition of 1 mmol/L DEC. Scale bar 50 pA versus 1 sec. (L) Pooled interevent interval of mIPSCs in control and 1 mmol/L DEC. (M) Pooled charge transfer of mIPSCs after addition of 1 mmol/L DEC. DEC, decanoic acid. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.

36.28 ± 8.33 pA. In the presence of PER (10 µmol/L) there was no significant change in IEI (Fig. 2F; 88.93 ± 16.55 msec, n = 6, P = ns), amplitude (25.19 ± 3.82 pA, P > 0.05) or charge transfer (Fig. 2G; 16.46 ± 10.91 vs. 10.16 ± 0.54 pC, n = 6, P = 0.1). When we recorded sEPSCs (Fig. 2H), IEI was significantly increased from 173 ± 217 to 2361 ± 873 msec (P = 0.03) in the presence of PER (Fig. 2I). The effect of PER on amplitude did not reach statistical significance (19.87 ± 4.1 vs. 10.83 ± 2.92 pA; P = 0.06), but the charge transfer was significantly reduced (Fig. 2J; 341 ± 1622 vs. 169 ± 115 fC, n = 6, P = 0.03).

Discussion

This study confirms that AMPAR inhibition, either by DEC or PER, is effective in abolishing spontaneous epileptiform activity in human tissue from drug-resistant pediatric epilepsy patients through a direct reduction in excitatory neurotransmission.

DEC, a major constituent of the MCT KD, has previously been shown to have an anticonvulsant action in acute in vitro rat hippocampal slice models of epileptiform activity, acting through modulation of excitatory neurotransmission.3-5 In our human tissue LFP recordings, the anticonvulsant effects of DEC were clearly demonstrated at the 300 µmol/L concentration, consistent with reported therapeutic pediatric plasma concentrations.14,15 In WCPC experiments, the anticonvulsant mechanism was shown to be likely through the reduction of post-synaptic excitatory neurotransmission via AMPARs.

Similar effects were seen with PER, via a reduction in the frequency of EPSCs and overall charge transfer. These effects were observed in tissue from a wide array of epilepsy syndromes, and underline the importance of the AMPAR in understanding the development and treatment of the epilepsies. Like many aspects of epilepsy, it is not a simple case of ‘too much’ AMPAR activity leading to seizures, for example, in anti-AMPAR autoimmune encephalitis, antibodies generated against AMPAR epitopes lead to AMPAR internalization, thereby reducing excitatory drive while still causing temporal lobe seizures in man.16,17 Similarly, recent work in a rat model of chronic TLE in our laboratory suggests that seizures induce a profound loss of AMPAR expression in vulnerable networks.12 Hence, AMPARs would appear to play both causative and compensatory roles in seizures and epileptogenesis.

Currently, the management for children with drug-resistant epilepsy includes referral to an epilepsy surgery unit for assessment of suitability for resective surgery. Researchers have attempted to explore the role of the KD in improving seizure outcomes in epilepsy surgery patients with Focal Cortical Dysplasia Type II (the EDIBLE research study: www.edible.org.uk). While studies in human brain tissue do not provide a substitute for clinical trials in children, this preclinical study suggests that the MCT KD or PER may be effective in reducing seizure burden pre-operatively for these patients. Indeed, a synergistic therapeutic effect of DEC and PER was recently demonstrated in a study using in vitro epilepsy animal models and adult human tissue from brain tumor patients.4

One criticism of human epileptic tissue research is the lack of “control” tissue.18,19 For obvious ethical reasons, we cannot and will never have the opportunity to obtain pediatric “normal” brain tissue for the ideal control. However, this should not prevent the use of human tissue as an invaluable resource to study the true pathophysiological changes in pediatric drug-resistant epilepsy. Recent studies in human brain tissue have demonstrated the presence of extensive species-specific differences in neuron types and properties as compared to the rodent brain.20,21 A clear example of this is the expression of 5HT3 receptors, which are present on excitatory cells throughout the human forebrain, but expressed only on inhibitory GABA cells in rodent brain.22 Therefore, the use of human epileptic brain tissue could provide novel insights to complement preclinical animal model studies. This is of the particular importance of the testing of treatments in medically refractory epilepsy, as few animal models recapitulate fully the diversity of seizure types, localization and etiology of the patients seen in the clinic. In pediatric
Ampa Receptor Inhibition in Spontaneously Epileptic Human Brain Tissue

S. K. Wright et al.
epilepsy research, slice preparations from resected tissue are extremely valuable and rare, and provide a unique substrate for testing novel and approved compounds in pharmaco-resistant epilepsy.

In summary, this study shows the potential application of human tissue samples for epilepsy research and drug development. The heterogeneity of the human tissue samples is a true reflection of the variable etiology of refractory epilepsy and should be considered a strength of the human tissue approach to pediatric epilepsy research.

Acknowledgments

This work was supported by an Epilepsy Research UK Fellowship (SKW) and the Birmingham Children’s Hospital Research Fund (GLW). We gratefully acknowledge the help and assistance of the Birmingham Children’s Hospital Children’s Epilepsy Surgery Service (CESS) team and theatre staff.

Author Contributions

SKW, GLW, and SDG contributed to the conception and design of the study. SKW, GLW, SDG, SS, MAW, ARW, WBL, NM, SA, SP contributed to the acquisition and analysis of data. SKW, GLW, SDG, and MAW contribute to the drafting of the manuscript and figures.

Conflicts of Interests

SP has received speaker’s fees from Eisai, LivaNova, Novartis and Zogenix. GLW and SDG have been funded by GW Pharma for work unrelated to this paper.

References

1. Rogawski MA. AMPA receptors as a molecular target in epilepsy therapy. Acta Neurol Scand Suppl 2013;127:9–18.
2. Zwart R, Sher E, Ping X, et al. Perampanel, an antagonist of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models. J Pharmacol Exp Ther 2014;351:124–133.
3. Chang P, Augustin K, Boddam K, et al. Seizure control by decanoic acid through direct AMPA receptor inhibition. Brain 2016;139(Pt 2):431–443.
4. Augustin K, Williams S, Cunningham M, et al. Perampanel and decanoic acid show synergistic action against AMPA receptors and seizures. Epilepsia 2018;59:e172–e178.
5. Augustin K, Khabbush A, Williams S, et al. Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders. Lancet Neurol 2018;17:84–93.
6. Pellock JM, Arzimanoglou A, D’Cruz O, et al. Extrapolating evidence of antiepileptic drug efficacy in adults to children ≥2 years of age with focal seizures: the case for disease similarity. Epilepsia 2017;58:1686–1696.
7. D’Antuono M, Louvel J, Kohling R, et al. GABAA receptor-dependent synchronization leads to ictogenesis in the human dysplastic cortex. Brain 2004;127(Pt 7):1626–1640.
8. Avoli M, Bernasconi A, Mattia D, et al. Epileptiform discharges in the human dysplastic neocortex: in vitro physiology and pharmacology. Ann Neurol 1999;46:816–826.
9. Wickham J, Brodjegard NG, Vighagen R, et al. Prolonged life of human acute hippocampal slices from temporal lobe epilepsy surgery. Sci Rep 2018;8:4158.
10. Huberfeld G, Wittner L, Clemenceau S, et al. Perturbed chloride homeostasis and GABAergic signaling in human temporal lobe epilepsy. J Neurosci 2007;27:9866–9873.
11. Kramvis I, Mansvelder HD, Meredith RM. Neuronal life after death: electrophysiologic recordings from neurons in adult human brain tissue obtained through surgical resection or postmortem. Handb Clin Neurol 2018;150:319–333.
12. Needs HI, Henley BS, Cavallo D, et al. Changes in excitatory and inhibitory receptor expression and network activity during induction and establishment of epilepsy in the rat Reduced Intensity Status Epilepticus (RISE) model. Neuropharmacology 2019;158:107728.
13. Morgan NH, Stanford JM, Woodhall GL. Functional CB2 type cannabinoid receptors at CNS synapses. Neuropharmacology 2009;57:356–368.
14. Haidukewych D, Forsythe WI, Sills M. Monitoring octanoic and decanoic acids in plasma from children with intractable epilepsy treated with medium-chain triglyceride diet. Clin Chem 1982;28(4 Pt 1):642–645.
15. Sills MA, Forsythe WI, Haidukewych D. Role of octanoic and decanoic acids in the control of seizures. Arch Dis Child 1986;61:1173–1177.

16. Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009;65:424–434.

17. Peng X, Hughes EG, Moscato EH, et al. Cellular plasticity induced by anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies. Ann Neurol 2015;77:381–398.

18. Jones RS, da Silva AB, Whittaker RG, et al. Human brain slices for epilepsy research: pitfalls, solutions and future challenges. J Neurosci Methods 2016;260:221–232.

19. Kohling R, Avoli M. Methodological approaches to exploring epileptic disorders in the human brain in vitro. J Neurosci Methods 2006;155:1–19.

20. Kalmbach BE, Buchin A, Long B, et al. h-Channels contribute to divergent intrinsic membrane properties of supragranular pyramidal neurons in human versus mouse cerebral cortex. Neuron 2018;100:1194–1208.e5.

21. Hodge RD, Bakken TE, Miller JA, et al. Conserved cell types with divergent features in human versus mouse cortex. Nature 2019;573:61–68.

22. Parker RM, Barnes JM, Ge J, et al. Autoradiographic distribution of [3H]-(S)-zacopride-labelled 5-HT3 receptors in human brain. J Neurol Sci 1996;144:119–127. PubMed PMID: 8994113.